Enveric Biosciences (NASDAQ:ENVB) Trading Up 1.9% – What’s Next?

Enveric Biosciences, Inc. (NASDAQ:ENVB) shares shot up 1.9% on Monday . The stock traded as high as $1.6299 and last traded at $1.60. Approximately 83,980 shares changed hands during mid-day trading, a decline of 25% from the average session volume of 111,233 shares. The stock had previously closed at $1.57.

Analyst Ratings Changes

ENVB has been the topic of several research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Enveric Biosciences in a report on Friday, July 17th. Wall Street Zen raised Enveric Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, July 12th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Enveric Biosciences Stock Down 1.2%

The business has a 50-day moving average price of $1.53 and a two-hundred day moving average price of $2.25. The company has a market capitalization of $6.15 million, a price-to-earnings ratio of -0.07 and a beta of 1.13.

Enveric Biosciences (NASDAQ:ENVB) last posted its quarterly earnings results on Friday, May 15th. The company reported ($1.08) earnings per share (EPS) for the quarter.

About Enveric Biosciences

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.